CA Patent

CA2265630A1 — Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders

Assigned to Sugen LLC · Expires 1998-03-19 · 28y expired

What this patent protects

This invention is directed to methods and compositions for treating hyperproliferative skin disorders utilizing a quinazoline derivative as an active ingredient.

USPTO Abstract

This invention is directed to methods and compositions for treating hyperproliferative skin disorders utilizing a quinazoline derivative as an active ingredient.

Drugs covered by this patent

Patent Metadata

Patent number
CA2265630A1
Jurisdiction
CA
Classification
—
Expires
1998-03-19
Drug substance claim
No
Drug product claim
No
Assignee
Sugen LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.